Endo to buy Par Pharma for $8B to bulk up in injectables

Endo ($ENDP) is acquiring Par Pharmaceutical for $8 billion. It adds about 100 products from Par, such as generic injectables worth $1.3 billion in 2014 sales. Injectables are tougher to manufacture than pills, which means the competition is lower, garnering higher profitability. "This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A," Endo CEO Rajiv De Silva said. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.